Le Lézard
Classified in: Health
Subject: FDA

FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes

PLAINSBORO, N.J., Oct. 22, 2019 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.1 Fiasp®, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a healthcare professional or by subcutaneous multiple daily injection (MDI) in adults with diabetes.

There are estimated to be more than 350,000 insulin infusion pump users in the U.S.2,3,4 An insulin pump is a small, programmable, battery-operated device that delivers insulin under the skin. Fiasp® should be used in accordance with the insulin pump's instructions for use. Fiasp® is available in multiple dosing options for multiple daily injections (MDI) as well as continuous subcutaneous insulin infusion1:

"People living with diabetes are looking for treatment options that fit into their lifestyles and shifting schedules, and for many, an insulin pump is an important part of their regimen," said Todd Hobbs, vice president and U.S. chief medical officer of Novo Nordisk. "Since the launch of Fiasp®, we've heard time and again from the diabetes community about the need to make it available for adult insulin pump users. This label update will now enable adult patients to use Fiasp® in their pumps, which is an important part of our ongoing commitment to patient choice and meeting the needs of people living with type 1 and type 2 diabetes." 

The label change is based on the FDA's review of data from the onset 5 clinical trial, which confirmed the efficacy and safety of Fiasp® when used in insulin infusion pumps in adults with diabetes. 5 Fiasp® has been shown to be well-tolerated and effective in pumps releasing steady doses throughout the day and mealtime doses during meals. The pump should be programmed based on guidance from healthcare providers and the pump maker's instructions. 1

For information on cost and savings offers, including co-pay and patient assistance programs, visit Novocare.com.

About Fiasp®
Fiasp® is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Fiasp® is administered at the beginning of a meal or within 20 minutes after starting a meal.

About onset 5
The Fiasp® label expansion to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes was based on data from onset 5, a randomised, multicenter, multinational trial, which investigated the efficacy and safety of continuous subcutaneous insulin infusion of Fiasp® compared to NovoLog® in adults with type 1 diabetes.5  

Indications and Usage

What is Fiasp® (insulin aspart injection) 100 U/mL?

Important Safety Information

Do not share your Fiasp® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Who should not take Fiasp®?
Do not take Fiasp® if:

Before taking Fiasp® tell your health care provider about all your medical conditions including, if you:

Talk to your health care provider about low blood sugar and how to manage it.
How should I take Fiasp®?

What should I avoid while taking Fiasp®?

What are the possible side effects of Fiasp®?
Serious side effects can lead to death, including:

Your insulin dose may need to change because of:

Common side effects of Fiasp® may include:

Please see Prescribing Information for Fiasp at http://www.novo-pi.com/fiasp.pdf

About Novo Nordisk
Novo Nordisk is a global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 6,000 people throughout the country. For more information, visit novonordisk.us, Facebook, Instagram and Twitter.


  1. Fiasp [package insert]. Plainsboro, NJ: Novo Nordisk Inc; October 2019.
  2. Diabetes Care. 2015 Apr;38(4):716-22. doi: 10.2337/dc15-0168.
  3. J Clin Med. 2016 Jan; 5(1): 5. Published online 2016 Jan 4. doi: 10.3390/jcm5010005
  4. Diabetes Care. 2018 Aug;41(8):1579-1589. doi: 10.2337/dci18-0002. Epub 2018 Jun 23.
  5. Klonoff D, et al. Diabetes Obes Metab. 2019;21:961?967. doi: 10.1111/dom.13610

Fiasp® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2019 Novo Nordisk All rights reserved. US19FSP00188 October 2019

SOURCE Novo Nordisk

These press releases may also interest you

at 14:13
eHealth, Inc. , a leading private online health insurance exchange, announced today that the company plans to release second quarter 2020 financial results on July 23, 2020. Chief Executive Officer Scott Flanders and Chief Financial Officer Derek...

at 14:05
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company and a key global probiotics manufacturer, confirmed that its proprietary probiotic strain Bifidobacterium breve A1 (a.k.a. B. breve MCC1274) is safe and effective...

at 14:01
Sage Growth Partners (SGP) today announced findings from a new survey of U.S. physicians that assesses how COVID-19 has changed the way they deliver care?specifically how they have incorporated telehealth into their practices. The survey was...

at 14:00
Deborah Heart and Lung Center -- New Jersey's only specialty heart, lung, and vascular center, and an Alliance Partner of the Cleveland Clinic Heart, Vascular & Thoracic Institute -- has announced a new partnership with Sidney Kimmel Medical College...

at 14:00
CorVive is consistently encouraging their customers and endorsers alike to make the change to living a healthier lifestyle. A lifestyle where the customers and endorsers are able to enjoy their time with family and friends while being more active and...

at 14:00
DOCPACE, a provider of virtual waiting rooms and schedule recommendations to optimize patient demand, today announced a partnership with athenahealth, Inc. through the company's Marketplace program. As part of the athenahealth ® Marketplace, this...

News published on 22 october 2019 at 09:10 and distributed by: